Inhibition of localized thrombosis in P2Y1‐deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2003-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1538-7836.2003.00144.xPMID 12871312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel platelet inhibitors.

  2001cited by this paper
• Antiplatelet agents in tissue factor-induced blood coagulation.

  2001cited by this paper
• P2y(12), a new platelet ADP receptor, target of clopidogrel.

  2001cited by this paper
• Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.

  2001cited by this paper
• Nucleotide receptors: an emerging family of regulatory molecules in blood cells.

  2001cited by this paper
• The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.

  2001cited by this paper
• ADP Receptors of Platelets and their Inhibition

  2001cited by this paper
• Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.

  2001cited by this paper
• Influence of the genetic background on platelet function, microparticle and thrombin generation in the common laboratory mouse

  2001cited by this paper
• The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

  2000cited by this paper
• Desensitization of the Platelet Aggregation Response to ADP: Differential Down-regulation of the P2Y1 and P2cyc Receptors

  2000cited by this paper
• Effect of Clopidogrel on Thrombin Generation in Platelet-Rich Plasma in the Rat

  1999cited by this paper
• Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.

  1999cited by this paper
• Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice

  1999cited by this paper
• A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.

  1998cited by this paper
• Competitive and selective antagonism of P2Y1 receptors by N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphate

  1998cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  1996cited by this paper
• ADP receptors on platelets and ADP-selective antiaggregating agents.

  1996cited by this paper
• Importance of platelets in experimental venous thrombosis in the rat.

  1992cited by this paper
• Inhibition by Recombinant Hirudins of Experimental Venous Thrombosis and Disseminated Intravascular Coagulation Induced by Tissue Factor in Rats

  1990cited by this paper
• Pharmaceutical Statistics: Practical and Clinical Applications

  1985cited by this paper
• [Platelet aggregation: a tool for clinical investigation and pharmacological study. Methodology].

  1983cited by this paper
• Thrombosis in the presence of vascular stasis.

  1962cited by this paper

• Discovery of 1-Difluoromethyl-3-(3-cyanophenyl)-6-[4-(trifluoromethoxy)phenyl]imidazo[1,5-a]pyrazin-8-(7H)-one as a Potent P2Y1 Antagonist for the Treatment of Ischemic Stroke and Myocardial Infarction.

  2025cites this paper
• The role of P2Y1R in cardiovascular diseases and recent development of P2Y1R antagonists.

  2025cites this paper
• Platelet Membrane Receptors and Signalling Pathways.

  2025cites this paper
• Design and Pharmacological Characterization of a Novel Antithrombotic P2Y1 Receptor-Based Vaccine

  2025cites this paper
• Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.

  2025cites this paper
• Molecular and metabolic landscape of adenosine triphosphate-induced cell death in cardiovascular disease

  2024cites this paper
• Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

  2023cites this paper
• Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment

  2023cites this paper
• Withaferin A for COVID-19: a Network Pharmacology Approach

  2023cites this paper
• Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice.

  2022cites this paper
• Plant extract‐based synthesis of metallic nanomaterials, their applications, and safety concerns

  2022cites this paper
• Understanding stenosis-induced platelet aggregation on a chip by high-speed optical imaging

  2021cites this paper
• Inflammatory macrophages exacerbate neutrophil-driven joint damage through ADP/P2Y1 signaling in rheumatoid arthritis

  2021cites this paper
• Platelet Purinergic Receptors in Thrombosis and Inflammation

  2020cites this paper
• The role of bone marrow-derived cells in venous thromboembolism

  2020cites this paper
• Potential Therapeutic Applications of P2 Receptor Antagonists: from Bench to Clinical Trials.

  2019cites this paper
• The Platelet P2 Receptors

  2019cites this paper
• A complementary role for tetraspanin superfamily member TSSC6 and ADP purinergic P2Y12 receptor in platelets.

  2018cites this paper
• Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y1 receptor antagonists.

  2018cites this paper
• Generation of procoagulant collagen‐ and thrombin‐activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage

  2018cites this paper
• The P2Y1 receptor-mediated leukocyte adhesion to endothelial cells is inhibited by melatonin

  2017cites this paper
• Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases

  2017cites this paper
• Purinergic P2Y6 receptors: A new therapeutic target of age‐dependent hypertension

  2017cites this paper
• Advances in Antiplatelet Agents

  2017cites this paper
• The P2 Receptors

  2017cites this paper
• A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection

  2016cites this paper
• Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.

  2016cites this paper
• The Role of Platelets in Venous Thromboembolism

  2016cites this paper
• Identification of Highly Promising Antioxidants/Neuroprotectants Based on Nucleoside 5'-Phosphorothioate Scaffold. Synthesis, Activity, and Mechanisms of Action.

  2015cites this paper
• Characterization of a Novel Function-Blocking Antibody Targeted Against the Platelet P2Y1 Receptor

  2015influential citation
• [Anti-platelets without a bleeding risk: novel targets and strategies].

  2015cites this paper
• Hot Water Extracts of the Royal Sun Mushroom, Agaricus brasiliensis (Higher Basidiomycetes), Inhibit Platelet Activation via the P2Y1 Receptor.

  2015cites this paper
• A complementary role for tetraspanin superfamily member CD151 and ADP purinergic P2Y12 receptor in platelets

  2015cites this paper
• Extracellular ATP metabolism on vascular endothelial cells: A pathway with pro-thrombotic and anti-thrombotic molecules.

  2015cites this paper
• Thrombosis: Novel nanomedical concepts of diagnosis and treatment.

  2015cites this paper
• Photoinducible penetration enhancement and drug release for cancer treatment.

  2014cites this paper
• 4‐Benzothiazole‐7‐hydroxyindolinyl Diaryl Ureas Are Potent P2Y1 Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution

  2014cites this paper
• Cardiovascular therapy through nanotechnology – how far are we still from bedside?

  2014cites this paper
• Group VIB Calcium-Independent Phospholipase A2 (iPLA2γ) Regulates Platelet Activation, Hemostasis and Thrombosis in Mice

  2014cites this paper
• Nanoparticle systems that exploit host biology for diagnosis and treatment of disease

  2014cites this paper
• Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

  2013cites this paper
• Chapter 20 – Platelet Thrombus Formation in Flowing Blood

  2013cites this paper
• Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis

  2013cites this paper
• Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis

  2013cites this paper
• Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

  2013cites this paper
• RhoG Protein Regulates Platelet Granule Secretion and Thrombus Formation in Mice

  2013cites this paper
• Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs

  2013cites this paper
• The P2Y receptors and thrombosis

  2013cites this paper
• ADP Receptor Antagonists

  2013cites this paper
• New perspectives in antiplatelet therapy.

  2012cites this paper
• Effects of P2Y1 receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel

  2012cites this paper
• Instituto Oswaldo Cruz

  2012cites this paper
• A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis

  2012cites this paper
• Faculty of Medicine and Health Sciences School of Biomedical Sciences

  2011cites this paper
• Nucleotide regulation of vascular system

  2011cites this paper
• BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase

  2011influential citation
• Major Contribution of the P2Y1 Receptor in Purinergic Regulation of TNF&agr;-Induced Vascular Inflammation

  2011cites this paper
• P2 receptors and platelet function

  2011cites this paper
• Évaluation pré-clinique et clinique de deux nouvelles stratégies dans le traitement des maladies cardiovasculaires : activité anti-thrombotique de l'inhibition du récepteur P2Y1 et activité anti-inflammatoire de l'inhibition du récepteur PAR-1

  2010cites this paper
• Platelets in Arterial Thrombosis

  2010cites this paper
• Новые антиагреганты блокаторы тромбоцитарных Р2-рецепторов

  2010cites this paper
• Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization

  2010cites this paper
• Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death

  2010cites this paper
• Antithrombotic drug therapy in cardiovascular disease

  2010cites this paper
• Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism.

  2010cites this paper
• Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo.

  2009cites this paper
• Overview of murine thrombosis models.

  2008cites this paper
• Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature

  2008cites this paper
• Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists.

  2008cites this paper
• Reduced Atherosclerotic Lesions in P2Y1/Apolipoprotein E Double-Knockout Mice: The Contribution of Non–Hematopoietic-Derived P2Y1 Receptors

  2008cites this paper
• P2 receptors, platelet function and pharmacological implications

  2008cites this paper
• P2Y-1 Receptor

  2008cites this paper
• Nouveaux paramètres d'exploration de la fonction plaquettaire en clinique : thrombose tardive, profilage micro-membranaire et détection de sous-populations cellulaires

  2008cites this paper
• Platelet receptor redox regulation

  2008cites this paper
• Individual variation in in vitro efficacy of antiplatelet medication - aspirin and clopidogrel

  2007cites this paper
• CHAPTER 10 – The Platelet P2 Receptors

  2007cites this paper
• Both ADP and Thrombin Regulate Arteriolar Thrombus Stabilization and Embolization, but Are Not Involved in Initial Hemostasis as Induced by Micropuncture

  2007cites this paper
• CHAPTER 18 – Platelet Thrombus Formation in Flowing Blood

  2007cites this paper
• Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity.

  2007cites this paper
• CHAPTER 61 – ADP Receptor Antagonists

  2007cites this paper
• G-protein dependent platelet signaling--perspectives for therapy.

  2006cites this paper
• Calmodulin interacts with the platelet ADP receptor P2Y1.

  2006cites this paper
• P2X1 stimulation promotes thrombin receptor‐mediated platelet aggregation

  2006cites this paper
• MRS2500 [2-Iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a Potent, Selective, and Stable Antagonist of the Platelet P2Y1 Receptor with Strong Antithrombotic Activity in Mice

  2006influential citation
• The platelet ATP and ADP receptors.

  2006cites this paper
• The role of ADP receptors in platelet function.

  2006cites this paper
• ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X1

  2006cites this paper
• Regulation of platelet functions by P2 receptors.

  2006cites this paper
• The platelet P2 receptors in arterial thrombosis.

  2006cites this paper
• The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.

  2006cites this paper
• ERK 2 activation in arteriolar and venular murine thrombosis : platelet receptor GPIb vs . P 2 X 1

  2006cites this paper
• International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy

  2006cites this paper
• Is the P2Y1 receptor a better target for antithrombotic drugs

  2005cites this paper
• Importance of Platelet Phospholipase Cγ2 Signaling in Arterial Thrombosis as a Function of Lesion Severity

  2005cites this paper
• MRS2500, a potent, selective and stable antagonist of the P2Y1 receptor, with strong antithrombotic activity in mice

  2005cites this paper
• The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.

  2005cites this paper
• The Platelet P2 Receptors in Thrombosis

  2005influential citation
• Platelet Aggregation and Adenosine Diphosphate/Adenosine Triphosphate Receptors: A Historical Perspective

  2005cites this paper
• The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice

  2005cites this paper
• Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4′,4″,4″′-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt]

  2005cites this paper